Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies.
Alzheimer’s disease
Dementia with Lewy bodies
a-synuclein
beta-amyloid
biomarkers
cerebrospinal fluid
phospho-tau
tau
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
28 Apr 2022
28 Apr 2022
Historique:
received:
20
02
2022
revised:
22
04
2022
accepted:
27
04
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
The use and interpretation of diagnostic cerebrospinal fluid (CSF) biomarkers for neurodegenerative disorders, such as Dementia with Lewy bodies (DLB), represent a clinical challenge. According to the literature, the composition of CSF in DLB patients varies. Some patients present with reduced levels of amyloid, others with full Alzheimer Disease CSF profile (both reduced amyloid and increased phospho-tau) and some with a normal profile. Some patients may present with abnormal levels of a-synuclein. Continuous efforts will be required to establish useful CSF biomarkers for the early diagnosis of DLB. Given the heterogeneity of methods and results between studies, further validation is fundamental before conclusions can be drawn.
Identifiants
pubmed: 35630029
pii: medicina58050612
doi: 10.3390/medicina58050612
pmc: PMC9144333
pii:
doi:
Substances chimiques
Biomarkers
0
tau Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Alzheimers Res Ther. 2018 Mar 1;10(1):27
pubmed: 29490691
Brain Sci. 2021 Jan 17;11(1):
pubmed: 33477387
Neurobiol Dis. 2020 Jul;141:104876
pubmed: 32339655
Lancet Neurol. 2011 Mar;10(3):230-40
pubmed: 21317042
J Alzheimers Dis. 2016 Aug 18;54(1):287-95
pubmed: 27567832
Mov Disord. 2016 Jun;31(6):898-905
pubmed: 26878815
Neurology. 2021 Aug 31;97(9):e930-e940
pubmed: 34210822
Dement Geriatr Cogn Disord. 2005;20(2-3):89-94
pubmed: 15976504
PLoS One. 2013 Nov 25;8(11):e81654
pubmed: 24282614
Alzheimers Res Ther. 2019 Oct 10;11(1):83
pubmed: 31601267
Alzheimers Res Ther. 2014 Oct 16;6(5-8):72
pubmed: 25478030
Geriatr Psychol Neuropsychiatr Vieil. 2018 Jun 1;16(2):174-180
pubmed: 29877185
Neurology. 2012 Jan 3;78(1):47-54
pubmed: 22170879
J Neurol Sci. 2020 Aug 15;415:116886
pubmed: 32428759
J Alzheimers Dis. 2017;59(4):1139-1152
pubmed: 28731443
Mov Disord. 2016 Aug;31(8):1203-8
pubmed: 27296778
Mov Disord. 2022 May;37(5):993-1003
pubmed: 35137973
J Neurol. 2018 Oct;265(10):2295-2301
pubmed: 30083953
J Alzheimers Dis. 2016;51(4):1069-83
pubmed: 26923009
Dement Geriatr Cogn Disord. 2011;31(4):309-16
pubmed: 21502762
Arch Neurol. 2003 Sep;60(9):1218-22
pubmed: 12975286
Lancet Neurol. 2011 Nov;10(11):1015-25
pubmed: 22014436
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Mov Disord. 2021 Mar;36(3):767-771
pubmed: 33285015
Front Neurol. 2022 Jan 31;12:805135
pubmed: 35173668
Dement Geriatr Cogn Disord. 2019;47(4-6):289-296
pubmed: 31311013
Brain. 2018 Jul 1;141(7):2181-2193
pubmed: 29878075
Nat Neurosci. 2019 Jul;22(7):1099-1109
pubmed: 31235907
BMC Med. 2018 Mar 6;16(1):34
pubmed: 29510692
Mov Disord. 2022 Apr;37(4):669-683
pubmed: 35122299
Acta Neurol Scand. 2019 Jan;139(1):76-81
pubmed: 30229861